Shanghai Henlius Biotech (HKSE:02696) Common Stock : HK$580 Mil (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Shanghai Henlius Biotech Common Stock?

Shanghai Henlius Biotech's quarterly common stock declined from Dec. 2023 (HK$594 Mil) to Jun. 2024 (HK$585 Mil) and declined from Jun. 2024 (HK$585 Mil) to Dec. 2024 (HK$580 Mil).

Shanghai Henlius Biotech's annual common stock declined from Dec. 2022 (HK$607 Mil) to Dec. 2023 (HK$594 Mil) and declined from Dec. 2023 (HK$594 Mil) to Dec. 2024 (HK$580 Mil).

Shanghai Henlius Biotech Common Stock Historical Data

The historical data trend for Shanghai Henlius Biotech's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Henlius Biotech Common Stock Chart

Shanghai Henlius Biotech Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Common Stock

Get a 7-Day Free Trial

644.28

665.49

606.93

594.46

580.27

Shanghai Henlius Biotech Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Common Stock	Get a 7-Day Free Trial										606.93	594.46	594.46	585.10	580.27

Shanghai Henlius Biotech Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Shanghai Henlius Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Henlius Biotech Inc (HKSE:02696) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

B8 Building, No. 188 Yizhou Road, 11th Floor, Xuhui District, Shanghai, CHN, 200233

Website

https://www.henlius.com

Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and innovative biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China and Overseas. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.

Executives

Qatar Investment Authority	2201 Interest of corporation controlled by you
Ubs Group Ag
Golden Valley Value Select Master Fund	2101 Beneficial owner
Vistra Trust (singapore) Pte. Limited	2301 Trustee
Lvc Sg Management Pte. Ltd.	2201 Interest of corporation controlled by you
Lvc Management Holdings Limited	2201 Interest of corporation controlled by you
Lin Lijun	2201 Interest of corporation controlled by you
Shanghai Fosun High Technology (group) Co., Ltd.	2201 Interest of corporation controlled by you
Shanghai Fosun Pharmaceutical (group) Co., Ltd.	2201 Interest of corporation controlled by you
Guo Guangchang	2201 Interest of corporation controlled by you
Fosun International Limited	2201 Interest of corporation controlled by you
Fosun International Holdings Ltd.	2201 Interest of corporation controlled by you
Fosun Industrial Co., Limited	2101 Beneficial owner
Fosun Holdings Limited	2201 Interest of corporation controlled by you
Liu Scott Shi-kau	2201 Interest of corporation controlled by you

Shanghai Henlius Biotech Headlines

No Headlines